Hsiang-Fu Kung

Hsiang-Fu Kung

Auto-generated profile, based on publicly available information

Hsiang-Fu Kung

Stanley Ho Centre for Emerging Infectious Diseases, The Chinese University of Hong Kong, Shatin, Hong Kong

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 June 2007 in Hepatology
Verified
Journal Article
Open access
PDF file
Yangchao ChenYangchao Chen
Yangchao Chen
MLMarie C. Lin
Marie C. Lin
HYHong Yao
Hong Yao
HWHua Wang
Hua Wang
AZAi-Qun Zhang
Ai-Qun Zhang
HKHsiang-Fu Kung
Hsiang-Fu Kung
Enhancer of zeste homolog 2 (EZH2) has been shown to be overexpressed in hepatocellular (HCC). We investigated the potential role of EZH2 in HCC tumorigenesis and examined the usefulness of RNA interference (RNAi) targeting EZH2 as a form of HCC treatment. Lentivirus-mediated RNAi was employed to knock-down EZH2 expression in human hepatoma cells to study the function of EZH2 in tumorigenesis and evaluate the treatment efficacy. Lentivirus-mediated RNAi effectively reduced EZH2 expression. Suppression of EZH2 in HCC cells significantly reduced their growth rate in vitro and markedly diminished their tumorigenicity in vivo. Moreover, in a mice model of established large-sized HCC, we showed that intratumor injection of lentiviral (Lenti)-shRNA (short hairpin RNA) or siRNA (small interfering RNA) targeting EZH2 produced significant tumor regression. To understand its molecular mechanism of action, we employed proteomic profiling technique and found that stathmin 1 is the downstream target of EZH2, as Lenti-shEZH2 treatment decreased stathmin protein expression, and ectopic overexpression of stathmin prevented Lenti-shEZH2 mediated tumor growth inhibition. Conclusion: Results from our study suggested for the first time that EZH2 plays a key role in HCC tumorigenesis, and is a novel therapeutic target for HCC. (HEPATOLOGY 2007;46:200–208.)

23 November 2010 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
FLFei‐Fei Lan
Fei‐Fei Lan
HWHua Wang
Hua Wang
Yangchao ChenYangchao Chen
Yangchao Chen
CCChu‐Yan Chan
Chu‐Yan Chan
SNSamuel S. Ng
Samuel S. Ng
HKHsiang‐Fu Kung
Hsiang‐Fu Kung
ZMicroRNAs (miRNAs) are endogenously expressed small noncoding RNAs that regulate approximately one‐third of human genes at post‐transcription level. Previous studies have shown that miRNAs were implicated in many cellular processes and participated in the progress of various tumors including hepatocellular carcinoma (HCC). Among all miRNAs, the let‐7 family is well recognized to play pivotal roles in tumorigenesis by functioning as potential growth suppressor. In the present study, we aimed to investigate the role of let‐7 family, particularly the hsa‐let‐7g, in the molecular pathogenesis of HCC. By use of MTT, qPCR, Western blotting and 2‐dimensional electrophoresis (2‐DE), over‐expression of hsa‐let‐7g was found to inhibit the proliferation of HCC cell line via negative and positive regulations of c‐Myc and p16INK4A, respectively. The expression of hsa‐let‐7g was noted to be markedly lowered in the HepG2, Hep3B and Huh7 cells, yet higher in the Bel‐7404 HCC cell line. Proliferation of HCC cell line was significantly inhibited after the transfection of hsa‐let‐7g mimics, while hsa‐let‐7g inhibitor transfection exerted an opposite effect. Concurrently, the mRNA and protein levels of c‐Myc were found significantly decreased in HepG2 cells after transfection of hsa‐let‐7g mimics, but obviously increased in Bel‐7404 cells after transfection of hsa‐let‐7g inhibitor. As revealed by 2‐DE, a significant upregulation of p16INK4A was revealed after the gain‐of‐function study using hsa‐let‐7g. Therefore, we suggest that hsa‐let‐7g may act as a tumor suppressor gene that inhibits HCC cell proliferation by downregulating the oncogene, c‐Myc, and upregulating the tumor suppressor gene, p16INK4A.

4 June 2013 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
SLShuilong Leng
Shuilong Leng
YHYanli Hao
Yanli Hao
DDDaobing Du
Daobing Du
SXShanyan Xie
Shanyan Xie
LHLepeng Hong
Lepeng Hong
HKHsiang‐Fu Kung
Hsiang‐Fu Kung
Ursolic acid (UA) has been reported to possess anticancer activities. Although some of the anticancer activities of UA have been explained by its apoptosis‐inducing properties, the mechanisms underlying its anticancer actions are largely unknown. We have found that UA‐activated autophagy induced cytotoxicity and reduced tumor growth of cervical cancer cells TC‐1 in a concentration‐dependent manner. UA did not induce apoptosis of TC‐1 cells in vitro as determined by annexin V/propidium iodide staining, DNA fragmentation, and Western blot analysis of the apoptosis‐related proteins. We found that UA increased punctate staining of light chain 3 (LC3), which is an autophagy marker. LC3II, the processed form of LC3I which is formed during the formation of double membranes, was induced by UA treatment. These results were further confirmed by transmission electron microscopy. Wortmannin, an inhibitor of autophagy, and a small interfering RNA (siRNA) for autophagy‐related genes (Atg5) reduced LC3II and simultaneously increased the survival of TC‐1 cells treated with UA. We also found that LC3II was significantly reduced and that survival was increased in Atg5−/− mouse embryonic fibroblast (MEF) cells compared to Atg5+/+ MEF cells under UA treatment. However, silencing BECN1 by siRNA affected neither the expression of LC3II nor the survival of TC‐1 cells under UA treatment. These results suggest that autophagy is a major mechanism by which UA kills TC‐1 cells. It is Atg5 rather than BECN1 that plays a crucial role in UA‐induced autophagic cell death in TC‐1 cells. The activation of autophagy by UA may become a potential cancer therapeutic strategy complementing the apoptosis‐based therapies. Furthermore, regulation of Atg5 may improve the efficacy of UA in cancer treatment.

24 August 2010 in Computational Biology and Chemistry
Verified
Journal Article
Closed access
SLSheng Lin
Sheng Lin
WCWilliam K.C. Cheung
William K.C. Cheung
SCShen Chen
Shen Chen
GLGang Lu
Gang Lu
ZWZifeng Wang
Zifeng Wang
HKHsiang-Fu Kung
Hsiang-Fu Kung

13 January 2009 in Proteomics
Verified
Journal Article
Closed access
PDF file
XWXin Wang
Xin Wang
Yangchao ChenYangchao Chen
Yangchao Chen
QHQuan-Bin Han
Quan-Bin Han
CCChu‐Yan Chan
Chu‐Yan Chan
HWHua Wang
Hua Wang
HKHsiang‐Fu Kung
Hsiang‐Fu Kung

14 September 2010 in Journal of Neuro-Oncology
Verified
Journal Article
Open access
PDF file
FYFang Yu
Fang Yu
SNSamuel S. M. Ng
Samuel S. M. Ng
Billy.K.C ChowBilly.K.C Chow
Billy.K.C Chow
JSJohnny Sze
Johnny Sze
GLGang Lu
Gang Lu
MLMarie C. M. Lin
Marie C. M. Lin
Interferon-induced transmembrane protein 1 (IFITM1) has recently been identified as a new molecular marker in human colorectal cancer. However, its role in glioma carcinogenesis is not known. In this study, we demonstrated that suppression of IFITM1 expression significantly inhibited proliferation of glioma cells in a time-dependent manner. The growth inhibitory effect was mediated by cell cycle arrest. Furthermore, IFITM1 knockdown significantly inhibited migration and invasion of glioma cells, which could be attributed to decreased expression and enzymatic activity of matrix metalloproteinase 9. Taken together, these results suggest that IFITM1 is a potential therapeutic target for gliomas.